Frequently Asked Questions
The market is segmented based on , By Disease Type (Hurler Syndrome, Niemann-Pick Disease, Tay-Sachs Disease, Gaucher Disease, Fabry Disease, Krabbe Disease, Others), Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy), Route of Administration (Oral, Parenteral, Others), End User (Hospital and Clinics, Diagnostic Laboratories, Others) – Industry Trends and Forecast to 2030.
.
The Global Inherited Metabolic Disorders Testing Market size was valued at USD 603.40 USD Million in 2022.
The Global Inherited Metabolic Disorders Testing Market is projected to grow at a CAGR of 8.1% during the forecast period of 2023 to 2030.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
